Studies Investigating Response-Adapted Therapy in HL
| Results | ||||
| Study | Patient population | Methodology | PET+ | PET− |
| Gallamini, 2011 (51) | 165 HL patients (78 limited, 87 advanced) | PET-2 (ABVD); PET− completed 6 more cycles; PET+ escalated to 4 cycles of BEACOPP, 4 cycles BEACOPP | 2-y FFS: 65% | 2-y FFS: 92% |
| Raemaekers, 2014 (26) | 1,137 early-HL patients (444 favorable, 693 unfavorable) | PET-2 (ABVD); PET− completed 2 more cycles if favorable, 4 more cycles if unfavorable; PET+ escalated to 2 cycles BEACOPP, radiotherapy | NA | NA |
| Casasnovas, 2015 (23) | 782 advanced/bulky-HL patients | PET-2 (BEACOPP); PET− deescalated to 4 cycles ABVD; PET+ completed 4 more cycles; controls completed 6 cycles BEACOPP | 2-y PFS: 72.9% | 2-y PFS: 92.8% |
| Ganesan, 2015 (22) | 50 advanced/bulky-HL patients | PET-2 (ABVD); PET− completed 4 more cycles; PET+ escalated to 4 cycles BEACOPP | 2-y EFS: 50% | 2-y EFS: 82% |
| Radford, 2015 (25) | 602 limited-HL patients | PET-3 (ABVD); PET− underwent radiotherapy or no therapy; PET+ completed 1 more cycle or radiotherapy | PFS: 87.6% | PFS: 92.3% (radiotherapy), 88.6% (no radiotherapy) |
| Straus, 2015 (52) | 164 limited-HL patients | PET-2 (ABVD); PET− completed 2 more cycles; PET+ escalated to 2 cycles BEACOPP, radiotherapy | 3-y PFS: 66% | 3-y PFS: 92% |
| Press, 2016 (24) | 358 advanced-HL patients | PET-2 (ABVD); PET− completed 2 more cycles; PET+ escalated to 6 cycles BEACOPP | 2-y PFS: 64% | 2-y PFS: 82% |
| Zinzani, 2016 (53) | 519 advanced-HL patients | PET-2 (ABVD); PET− completed 4 more cycles; PET+ escalated to salvage therapy, ASCT | 2-y PFS: 76% | 2-y PFS: 81% |
FFS = failure-free survival; NA = not applicable; EFS = event-free survival.